Vendor Drug Reports
Overview
The following is a repository of Vendor Drug-related reports.
Administration
Medication Therapy Management (MTM)
Medication therapy management (MTM) is a service, provided by pharmacists in collaboration with physicians and other healthcare providers, to enhance a patient’s knowledge of medications and increase adherence to prescription medication regimens, and also to detect potential adverse drug events and patterns of over-use or under-use of prescription drugs. MTM is provided to actively manage overall drug therapies and may consist of medication reviews, pharmacotherapy consults, disease management support, drug therapy management, drug safety surveillance, and health and wellness education.
Rider 49 requires the Health and Human Services Commission (HHSC) to implement a MTM pilot program aimed at reducing adverse drug events and related medical costs for a subset of high-risk Texas Medicaid clients. The interim report is a summary of the first five months of the MTM pilot program operation and includes interim data and outcomes. The interim report focuses on pharmacy and client enrollment; patient’s needs and corresponding MTM interventions; the outcome of the interventions; and estimated cost savings for the reporting period (April 27, 2012, to September 19, 2012). A final report will be produced in May 2013.
Clinical and Economic Outcomes of the Texas Medicaid Medication Therapy Management (MTM) Pilot
Medicaid Drug Utilization Review Annual Reports
The Social Security Act requires each state to submit an annual report on the operation of its Medicaid Drug Utilization Review program to the Centers for Medicare & Medicaid Services.
Drug Use and Expenditure Patterns – Quarterly Reports
The following reports provide prescription drug use and expenditure information for the most prescribed individual drugs and therapeutic drug classes. Every quarter the year-to-date report is updated and a new set of quarterly reports is added. The state fiscal year runs from September through August.
| Timeframe | Top 100 Prescription Drugs |
Top 50 Therapeutic Classes |
|---|---|---|
| Fiscal Year to Date through Quarter 4 | YTD through Q4 by Expenditure YTD through Q4 by Drug Use |
Top 50 TC YTD by Expenditure |
| Quarter 4 | Q4 by Expenditure Q4 by Drug Use |
Top 50 TC Q4 by Expenditure |
| Quarter 3 | Q3 by Expenditure Q3 by Drug Use |
Top 50 TC Q3 by Expenditure |
| Quarter 2 | Q2 by Expenditure Q2 by Drug Use |
Top 50 TC Q2 by Expenditure |
| Quarter 1 | Q1 by Expenditure Q1 by Drug Use |
Top 50 TC Q1 by Expenditure |
| Timeframe | Top 100 Prescription Drugs |
Top 50 Therapeutic Classes |
|---|---|---|
| Fiscal Year to Date through Quarter 4 | YTD through Q4 by Expenditure YTD through Q4 by Drug Use |
Top 50 TC YTD by Expenditure |
| Quarter 4 | Q4 by Expenditure Q4 by Drug Use |
Top 50 TC Q4 by Expenditure |
| Quarter 3 | Q3 by Expenditure Q3 by Drug Use |
Top 50 TC Q3 by Expenditure |
| Quarter 2 | Q2 by Expenditure Q2 by Drug Use |
Top 50 TC Q2 by Expenditure |
| Quarter 1 | Q1 by Expenditure Q1 by Drug Use |
Top 50 TC Q1 by Expenditure |